First patient included in the Opade Project

First patient included in the Opade Project

29 August 2023.

Salerno – It is with great excitement and optimism that we announce a significant milestone in the field of medical research. The OPADE Project (Optimise and predict antidepressant efficacy for patients suffering from major depressive disorders using multi-omics analysis and AI-predictive tool.) has reached a significant milestone by officially including its first patient in the study.

The OPADE Project, led by Fondazione Ebris, aims to revolutionise the healthcare landscape through the identification of key biomarkers that support the decision-making process of healthcare providers. This will be achieved through the development and implementation of a predictive tool based on AI (Artificial Intelligence) and ML (Machine Learning). The research focuses on the gut-brain axis, which plays a key role in Major Depressive Disorder (MDD).

During the project, extensive clinical research will be conducted in collaboration with various partners within the consortium. The complex interactions between genetics, epigenetics, the microbiome and inflammatory networks in relation to MDD will be explored. This multidisciplinary approach aims to provide a deeper understanding and a solid basis for future advances in the treatment of this medical condition.

The team behind the OPADE Project sincerely thanks the first patient for his courageous participation in this pioneering study. We also express our appreciation to the researchers and collaborators who make this cutting-edge work possible. The inclusion of this first patient marks the beginning of a promising journey towards a better understanding and treatment of MDD.

For more information on this groundbreaking project and its progress, we invite you to visit the official OPADE Project website: https://opade-project.eu/

About OPADE:

The OPADE Project (Optimise and predict antidepressant efficacy for patients suffering from major depressive disorders using multi-omics analysis and AI-predictive tool) is a leading research initiative aimed at identifying essential biomarkers and developing AI/ML tools to improve the medical decision-making process. The focus is on the gut-brain axis in Major Depressive Disorder (MDD) and seeks a deeper understanding of the related genetic, epigenetic, microbiological and inflammatory network aspects.